Global Granulomatosis with Polyangiitis Drug Market Research Report 2020

Global Granulomatosis with Polyangiitis Drug Market Research Report 2020

Table of Contents
1 Granulomatosis with Polyangiitis Drug Market Overview
1.1 Product Overview and Scope of Granulomatosis with Polyangiitis Drug
1.2 Granulomatosis with Polyangiitis Drug Segment by Type
1.2.1 Global Granulomatosis with Polyangiitis Drug Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 Benralizumab
1.2.3 Avacopan
1.2.4 Rituximab Biosimilar
1.2.5 Others
1.3 Granulomatosis with Polyangiitis Drug Segment by Application
1.3.1 Granulomatosis with Polyangiitis Drug Sales Comparison by Application: 2020 VS 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Granulomatosis with Polyangiitis Drug Market Size Estimates and Forecasts
1.4.1 Global Granulomatosis with Polyangiitis Drug Revenue 2015-2026
1.4.2 Global Granulomatosis with Polyangiitis Drug Sales 2015-2026
1.4.3 Granulomatosis with Polyangiitis Drug Market Size by Region: 2020 Versus 2026
2 Global Granulomatosis with Polyangiitis Drug Market Competition by Manufacturers
2.1 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Manufacturers (2015-2020)
2.2 Global Granulomatosis with Polyangiitis Drug Revenue Share by Manufacturers (2015-2020)
2.3 Global Granulomatosis with Polyangiitis Drug Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Granulomatosis with Polyangiitis Drug Manufacturing Sites, Area Served, Product Type
2.5 Granulomatosis with Polyangiitis Drug Market Competitive Situation and Trends
2.5.1 Granulomatosis with Polyangiitis Drug Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Granulomatosis with Polyangiitis Drug Players (Opinion Leaders)
3 Granulomatosis with Polyangiitis Drug Retrospective Market Scenario by Region
3.1 Global Granulomatosis with Polyangiitis Drug Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Granulomatosis with Polyangiitis Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
3.3.1 North America Granulomatosis with Polyangiitis Drug Sales by Country
3.3.2 North America Granulomatosis with Polyangiitis Drug Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
3.4.1 Europe Granulomatosis with Polyangiitis Drug Sales by Country
3.4.2 Europe Granulomatosis with Polyangiitis Drug Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Granulomatosis with Polyangiitis Drug Market Facts & Figures by Region
3.5.1 Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Region
3.5.2 Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
3.6.1 Latin America Granulomatosis with Polyangiitis Drug Sales by Country
3.6.2 Latin America Granulomatosis with Polyangiitis Drug Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
3.7.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country
3.7.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Granulomatosis with Polyangiitis Drug Historic Market Analysis by Type
4.1 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
4.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2015-2020)
4.3 Global Granulomatosis with Polyangiitis Drug Price Market Share by Type (2015-2020)
4.4 Global Granulomatosis with Polyangiitis Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Global Granulomatosis with Polyangiitis Drug Historic Market Analysis by Application
5.1 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)
5.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2015-2020)
5.3 Global Granulomatosis with Polyangiitis Drug Price by Application (2015-2020)
6 Company Profiles and Key Figures in Granulomatosis with Polyangiitis Drug Business
6.1 Bionovis SA
6.1.1 Corporation Information
6.1.2 Bionovis SA Description, Business Overview and Total Revenue
6.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Bionovis SA Products Offered
6.1.5 Bionovis SA Recent Development
6.2 Bristol-Myers Squibb Company
6.2.1 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Production Sites and Area Served
6.2.2 Bristol-Myers Squibb Company Description, Business Overview and Total Revenue
6.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Bristol-Myers Squibb Company Products Offered
6.2.5 Bristol-Myers Squibb Company Recent Development
6.3 ChemoCentryx Inc
6.3.1 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Production Sites and Area Served
6.3.2 ChemoCentryx Inc Description, Business Overview and Total Revenue
6.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
6.3.4 ChemoCentryx Inc Products Offered
6.3.5 ChemoCentryx Inc Recent Development
6.4 Coherus BioSciences Inc
6.4.1 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Production Sites and Area Served
6.4.2 Coherus BioSciences Inc Description, Business Overview and Total Revenue
6.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Coherus BioSciences Inc Products Offered
6.4.5 Coherus BioSciences Inc Recent Development
6.5 Genor BioPharma Co Ltd
6.5.1 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Production Sites and Area Served
6.5.2 Genor BioPharma Co Ltd Description, Business Overview and Total Revenue
6.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Genor BioPharma Co Ltd Products Offered
6.5.5 Genor BioPharma Co Ltd Recent Development
6.6 GlaxoSmithKline Plc
6.6.1 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Production Sites and Area Served
6.6.2 GlaxoSmithKline Plc Description, Business Overview and Total Revenue
6.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
6.6.4 GlaxoSmithKline Plc Products Offered
6.6.5 GlaxoSmithKline Plc Recent Development
6.7 Iltoo Pharma
6.6.1 Iltoo Pharma Granulomatosis with Polyangiitis Drug Production Sites and Area Served
6.6.2 Iltoo Pharma Description, Business Overview and Total Revenue
6.6.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Iltoo Pharma Products Offered
6.7.5 Iltoo Pharma Recent Development
6.8 Panacea Biotec Ltd
6.8.1 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Production Sites and Area Served
6.8.2 Panacea Biotec Ltd Description, Business Overview and Total Revenue
6.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
6.8.4 Panacea Biotec Ltd Products Offered
6.8.5 Panacea Biotec Ltd Recent Development
6.9 Sandoz International GmbH
6.9.1 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Production Sites and Area Served
6.9.2 Sandoz International GmbH Description, Business Overview and Total Revenue
6.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
6.9.4 Sandoz International GmbH Products Offered
6.9.5 Sandoz International GmbH Recent Development
6.10 The International Biotechnology Center (IBC) Generium
6.10.1 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Production Sites and Area Served
6.10.2 The International Biotechnology Center (IBC) Generium Description, Business Overview and Total Revenue
6.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2015-2020)
6.10.4 The International Biotechnology Center (IBC) Generium Products Offered
6.10.5 The International Biotechnology Center (IBC) Generium Recent Development
7 Granulomatosis with Polyangiitis Drug Manufacturing Cost Analysis
7.1 Granulomatosis with Polyangiitis Drug Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug
7.4 Granulomatosis with Polyangiitis Drug Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Granulomatosis with Polyangiitis Drug Distributors List
8.3 Granulomatosis with Polyangiitis Drug Customers
9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis
10 Global Market Forecast
10.1 Global Granulomatosis with Polyangiitis Drug Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Granulomatosis with Polyangiitis Drug by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Granulomatosis with Polyangiitis Drug by Type (2021-2026)
10.2 Granulomatosis with Polyangiitis Drug Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Granulomatosis with Polyangiitis Drug by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Granulomatosis with Polyangiitis Drug by Application (2021-2026)
10.3 Granulomatosis with Polyangiitis Drug Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Granulomatosis with Polyangiitis Drug by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Granulomatosis with Polyangiitis Drug by Region (2021-2026)
10.4 North America Granulomatosis with Polyangiitis Drug Estimates and Projections (2021-2026)
10.5 Europe Granulomatosis with Polyangiitis Drug Estimates and Projections (2021-2026)
10.6 Asia Pacific Granulomatosis with Polyangiitis Drug Estimates and Projections (2021-2026)
10.7 Latin America Granulomatosis with Polyangiitis Drug Estimates and Projections (2021-2026)
10.8 Middle East and Africa Granulomatosis with Polyangiitis Drug Estimates and Projections (2021-2026)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) Growth Rate Comparison by Type (2015-2026)
Table 2. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) Comparison by Application: 2020 VS 2026
Table 3. Global Granulomatosis with Polyangiitis Drug Market Size by Type (K Pcs) (US$ Million) (2020 VS 2026)
Table 4. Global Key Granulomatosis with Polyangiitis Drug Manufacturers Covered in This Study
Table 5. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Manufacturers (2015-2020)
Table 6. Global Granulomatosis with Polyangiitis Drug Sales Share by Manufacturers (2015-2020)
Table 7. Global Granulomatosis with Polyangiitis Drug Revenue (Million USD) by Manufacturers (2015-2020)
Table 8. Global Granulomatosis with Polyangiitis Drug Revenue Share by Manufacturers (2015-2020)
Table 9. Global Market Granulomatosis with Polyangiitis Drug Average Price (USD/Pcs) of Key Manufacturers (2015-2020)
Table 10. Manufacturers Granulomatosis with Polyangiitis Drug Sales Sites and Area Served
Table 11. Manufacturers Granulomatosis with Polyangiitis Drug Product Types
Table 12. Global Granulomatosis with Polyangiitis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Granulomatosis with Polyangiitis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Granulomatosis with Polyangiitis Drug as of 2019)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Main Points Interviewed from Key Granulomatosis with Polyangiitis Drug Players
Table 16. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Region (2015-2020)
Table 17. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2015-2020)
Table 18. Global Granulomatosis with Polyangiitis Drug Revenue (Million US$) by Region (2015-2020)
Table 19. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2015-2020)
Table 20. North America Granulomatosis with Polyangiitis Drug Sales by Country (2015-2020) (K Pcs)
Table 21. North America Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2015-2020)
Table 22. North America Granulomatosis with Polyangiitis Drug Revenue by Country (2015-2020) (US$ Million)
Table 23. North America Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2015-2020)
Table 24. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2015-2020) (K Pcs)
Table 25. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2015-2020)
Table 26. Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2015-2020) (US$ Million)
Table 27. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2015-2020)
Table 28. Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Region (2015-2020) (K Pcs)
Table 29. Asia Pacific Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2015-2020)
Table 30. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Region (2015-2020) (US$ Million)
Table 31. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2015-2020)
Table 32. Latin America Granulomatosis with Polyangiitis Drug Sales by Country (2015-2020) (K Pcs)
Table 33. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2015-2020)
Table 34. Latin America Granulomatosis with Polyangiitis Drug Revenue by Country (2015-2020) (US$ Million)
Table 35. Latin America Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2015-2020)
Table 36. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2015-2020) (K Pcs)
Table 37. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2015-2020)
Table 38. Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2015-2020) (US$ Million)
Table 39. Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2015-2020)
Table 40. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2015-2020)
Table 41. Global Granulomatosis with Polyangiitis Drug Sales Share by Type (2015-2020)
Table 42. Global Granulomatosis with Polyangiitis Drug Revenue (Million US$) by Type (2015-2020)
Table 43. Global Granulomatosis with Polyangiitis Drug Revenue Share by Type (2015-2020)
Table 44. Global Granulomatosis with Polyangiitis Drug Price (USD/Pcs) by Type (2015-2020)
Table 45. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Application (2015-2020)
Table 46. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)
Table 47. Global Granulomatosis with Polyangiitis Drug Sales Growth Rate by Application (2015-2020)
Table 48. Bionovis SA Granulomatosis with Polyangiitis Drug Corporation Information
Table 49. Bionovis SA Description and Business Overview
Table 50. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 51. Bionovis SA Main Product
Table 52. Bionovis SA Recent Development
Table 53. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Corporation Information
Table 54. Bristol-Myers Squibb Company Corporation Information
Table 55. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 56. Bristol-Myers Squibb Company Main Product
Table 57. Bristol-Myers Squibb Company Recent Development
Table 58. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Corporation Information
Table 59. ChemoCentryx Inc Corporation Information
Table 60. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 61. ChemoCentryx Inc Main Product
Table 62. ChemoCentryx Inc Recent Development
Table 63. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Corporation Information
Table 64. Coherus BioSciences Inc Corporation Information
Table 65. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 66. Coherus BioSciences Inc Main Product
Table 67. Coherus BioSciences Inc Recent Development
Table 68. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Corporation Information
Table 69. Genor BioPharma Co Ltd Corporation Information
Table 70. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 71. Genor BioPharma Co Ltd Main Product
Table 72. Genor BioPharma Co Ltd Recent Development
Table 73. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Corporation Information
Table 74. GlaxoSmithKline Plc Corporation Information
Table 75. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. GlaxoSmithKline Plc Main Product
Table 77. GlaxoSmithKline Plc Recent Development
Table 78. Iltoo Pharma Granulomatosis with Polyangiitis Drug Corporation Information
Table 79. Iltoo Pharma Corporation Information
Table 80. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. Iltoo Pharma Main Product
Table 82. Iltoo Pharma Recent Development
Table 83. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Corporation Information
Table 84. Panacea Biotec Ltd Corporation Information
Table 85. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Panacea Biotec Ltd Main Product
Table 87. Panacea Biotec Ltd Recent Development
Table 88. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Corporation Information
Table 89. Sandoz International GmbH Corporation Information
Table 90. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Sandoz International GmbH Main Product
Table 92. Sandoz International GmbH Recent Development
Table 93. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Corporation Information
Table 94. The International Biotechnology Center (IBC) Generium Corporation Information
Table 95. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. The International Biotechnology Center (IBC) Generium Main Product
Table 97. The International Biotechnology Center (IBC) Generium Recent Development
Table 98. Sales Base and Market Concentration Rate of Raw Material
Table 99. Key Suppliers of Raw Materials
Table 100. Granulomatosis with Polyangiitis Drug Distributors List
Table 101. Granulomatosis with Polyangiitis Drug Customers List
Table 102. Market Key Trends
Table 103. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 104. Key Challenges
Table 105. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) Forecast by Type (2021-2026)
Table 106. Global Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Type (2021-2026)
Table 107. Global Granulomatosis with Polyangiitis Drug Revenue (Million US$) Forecast by Type (2021-2026)
Table 108. Global Granulomatosis with Polyangiitis Drug Revenue (Million US$) Market Share Forecast by Type (2021-2026)
Table 109. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) Forecast by Application (2021-2026)
Table 110. Global Granulomatosis with Polyangiitis Drug Revenue (Million US$) Forecast by Application (2021-2026)
Table 111. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) Forecast by Region (2021-2026)
Table 112. Global Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Region (2021-2026)
Table 113. Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 114. Global Granulomatosis with Polyangiitis Drug Revenue Market Share Forecast by Region (2021-2026)
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Picture of Granulomatosis with Polyangiitis Drug
Figure 2. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type: 2020 VS 2026
Figure 3. Benralizumab Product Picture
Figure 4. Avacopan Product Picture
Figure 5. Rituximab Biosimilar Product Picture
Figure 6. Others Product Picture
Figure 7. Global Granulomatosis with Polyangiitis Drug Consumption Market Share by Application: 2020 VS 2026
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Others
Figure 11. Global Granulomatosis with Polyangiitis Drug Market Size 2015-2026 (US$ Million)
Figure 12. Global Granulomatosis with Polyangiitis Drug Sales Capacity (K Pcs) (2015-2026)
Figure 13. Global Granulomatosis with Polyangiitis Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Granulomatosis with Polyangiitis Drug Sales Share by Manufacturers in 2020
Figure 15. Global Granulomatosis with Polyangiitis Drug Revenue Share by Manufacturers in 2019
Figure 16. The Global 5 and 10 Largest Players: Market Share by Granulomatosis with Polyangiitis Drug Revenue in 2019
Figure 17. Granulomatosis with Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 18. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2015-2020)
Figure 19. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region in 2019
Figure 20. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2015-2020)
Figure 21. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region in 2019
Figure 22. North America Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2019
Figure 23. North America Granulomatosis with Polyangiitis Drug Revenue Market Share by Country in 2019
Figure 24. U.S. Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 25. U.S. Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 26. Canada Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 27. Canada Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 28. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2019
Figure 29. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Country in 2019
Figure 30. Germany Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 31. Germany Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 32. France Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 33. France Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 34. U.K. Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 35. U.K. Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Italy Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. Italy Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Russia Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Russia Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. Asia Pacific Granulomatosis with Polyangiitis Drug Sales Market Share by Region in 2019
Figure 41. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue Market Share by Region in 2019
Figure 42. China Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 43. China Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. Japan Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 45. Japan Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. South Korea Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. South Korea Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. India Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. India Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Australia Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. Australia Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Taiwan Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Taiwan Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Indonesia Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Indonesia Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Thailand Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 57. Thailand Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Malaysia Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 59. Malaysia Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Philippines Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 61. Philippines Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Vietnam Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. Vietnam Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2019
Figure 65. Latin America Granulomatosis with Polyangiitis Drug Revenue Market Share by Country in 2019
Figure 66. Mexico Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. Mexico Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Brazil Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. Brazil Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Argentina Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Argentina Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2019
Figure 73. Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Country in 2019
Figure 74. Turkey Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Turkey Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Saudi Arabia Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Saudi Arabia Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. U.A.E Granulomatosis with Polyangiitis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. U.A.E Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Sales Market Share of Granulomatosis with Polyangiitis Drug by Type (2015-2020)
Figure 81. Sales Market Share of Granulomatosis with Polyangiitis Drug by Type in 2019
Figure 82. Revenue Share of Granulomatosis with Polyangiitis Drug by Type (2015-2020)
Figure 83. Revenue Market Share of Granulomatosis with Polyangiitis Drug by Type in 2019
Figure 84. Global Granulomatosis with Polyangiitis Drug Sales Growth by Type (2015-2020) (K Pcs)
Figure 85. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)
Figure 86. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application in 2019
Figure 87. Global Revenue Share of Granulomatosis with Polyangiitis Drug by Application (2015-2020)
Figure 88. Global Revenue Share of Granulomatosis with Polyangiitis Drug by Application in 2020
Figure 89. Bionovis SA Total Revenue (US$ Million): 2019 Compared with 2018
Figure 90. Bristol-Myers Squibb Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 91. ChemoCentryx Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 92. Coherus BioSciences Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 93. Genor BioPharma Co Ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 94. GlaxoSmithKline Plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 95. Iltoo Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 96. Panacea Biotec Ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 97. Sandoz International GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 98. The International Biotechnology Center (IBC) Generium Total Revenue (US$ Million): 2019 Compared with 2018
Figure 99. Price Trend of Key Raw Materials
Figure 100. Manufacturing Cost Structure of Granulomatosis with Polyangiitis Drug
Figure 101. Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug
Figure 102. Granulomatosis with Polyangiitis Drug Industrial Chain Analysis
Figure 103. Channels of Distribution
Figure 104. Distributors Profiles
Figure 105. Porter's Five Forces Analysis
Figure 106. North America Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate Forecast (2021-2026)
Figure 107. North America Granulomatosis with Polyangiitis Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 108. Europe Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate Forecast (2021-2026)
Figure 109. Europe Granulomatosis with Polyangiitis Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 110. Latin America Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate Forecast (2021-2026)
Figure 111. Latin America Granulomatosis with Polyangiitis Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 112. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate Forecast (2021-2026)
Figure 113. Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 114. Asia Pacific Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate Forecast (2021-2026)
Figure 115. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 116. Bottom-up and Top-down Approaches for This Report
Figure 117. Data Triangulation
Figure 118. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs